<p><i><strong>Two of three patients achieved both complete remission and MRD-negative status</strong></i></p><p><i><strong>High response rates observed in earlier studies continue in ongoing mipletamig trial</strong></i></p><p><i><strong>Cohort 2 enrollment commencing</strong></i></p>

<p><i><strong>Aptevo's Peter Pavlik, PhD, to chair a session on "Bi and Multispecific Biologics" and will also give talk titled "Modular Multispecific Biotherapeutics: Rapid Therapeutic Design with the ADAPTIR&trade; Platform" at Cambridge Healthcare Institute's, Pep Talk 2025</strong></i></p>

After successfully completing a project in RNA splicing in cancer this January, BioMed X and Merck continue their oncology collaboration to explore tumor immunogenicity enhancers.

Growing Prevalence of Cancer and Increasing Investment in Research Driving Expansion

A work pioneered by Dr. Khan in India over a decade and his efforts have been widely hailed today in a glittering ceremony at Delhi where he was decorated with innovators award organized by Optimal Media Solutions.